Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

37.86 -1.25 (-3.20%)

Streaming Delayed Price Updated: 12:56 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play ↗

November 13, 2025

Canaccord said Viking’s obesity pipeline is worth far more than the current valuation.

Via Stocktwits

‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios ↗

November 11, 2025

Via Stocktwits

AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today ↗

November 11, 2025

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61.

Via Benzinga

Topics Stocks

Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗

November 06, 2025

Via Stocktwits

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera ↗

October 30, 2025

Via Stocktwits

2 Monster Stocks in the Making ↗

November 10, 2025

There might still be time to get in on the ground floor.

Via The Motley Fool

Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗

November 09, 2025

Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.

Via Stocktwits

Is There a Future for Viking Therapeutics? ↗

November 09, 2025

The weight loss drug company was counted out far too early in the summer, but investors are warming to it again.

Via The Motley Fool

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

Earnings Preview For Viking Therapeutics ↗

October 21, 2025

Via Benzinga

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain ↗

November 05, 2025

Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross.

Via Benzinga

Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils ↗

November 05, 2025

Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria.

Via Benzinga

Here's Why Shares in Viking Therapeutics Shot Higher in October ↗

November 05, 2025

Three factors took Viking's shares higher in the month.

Via The Motley Fool

Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets. ↗

November 04, 2025

It's a great idea to watch the latest moves of this expert investor.

Via The Motley Fool

Topics Artificial Intelligence

Prediction: The Next Eli Lilly Might Already Be Trading Under $50 ↗

November 03, 2025

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Via The Motley Fool

Should You Buy Viking Therapeutics Before Nov. 5? ↗

November 02, 2025

Viking's stock surged in one trading session after a positive clinical trial report last year.

Via The Motley Fool

3 Promising Growth Stocks That Are Down Around 60% From Their Highs ↗

October 31, 2025

These stocks may be down as of late, but investors shouldn't count them out in the long run.

Via The Motley Fool

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise ↗

October 31, 2025

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Via Stocktwits

10 Health Care Stocks Whale Activity In Today's Session ↗

October 30, 2025

Via Benzinga

Viking Therapeutics: High Risk, High Reward Play ↗

October 27, 2025

Via MarketBeat

Here's Why This Obesity Drug Company's Share Price Soared Today ↗

October 23, 2025

The company had positive updates on its clinical trials.

Via The Motley Fool

Topics Earnings

Why Is Viking Therapeutics Stock Rising Today? ↗

October 23, 2025

Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.

Via Benzinga

Viking Therapeutics Stock Soars After Morgan Stanley’s Price Target Implies A Potential 225% Upside ↗

October 23, 2025

Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.

Via Stocktwits

Topics Artificial Intelligence

Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies ↗

October 23, 2025

Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests.

Via Investor's Business Daily

Viking Therapeutics (NASDAQ:VKTX) Reports Q3 2025 Earnings Miss and 2.8% After-Hours Decline ↗

October 22, 2025

Viking Therapeutics Q3 2025 results show an earnings miss, with shares falling. The company's key Phase 3 obesity trial remains on track.

Via Chartmill

Topics Earnings

Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More ↗

October 20, 2025

Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.

Via Benzinga

Earnings Scheduled For October 22, 2025 ↗

October 22, 2025

Via Benzinga

These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond ↗

October 20, 2025

These companies are jockeying for position in a potential $150 billion market opportunity.

Via The Motley Fool

Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street? ↗

October 17, 2025

These stocks have climbed in the triple digits over the past few years.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

Headline News about Viking Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today